Omega Fund VI, L.P. Reports 8.4% Stake in ImageneBio, Inc. Following PIPE Financing

Omega Fund VI, L.P., along with its affiliates Omega Fund VI GP, L.P., Omega Fund VI GP Manager, Ltd., Claudio Nessi, and Otello Stampacchia, filed a Schedule 13D reporting an 8.4% beneficial ownership stake in ImageneBio, Inc. (formerly Ikena Oncology, Inc.). The reporting persons hold a total of 935,843 shares, which includes 454,982 shares of common stock and 480,861 shares issuable upon the exercise of pre-funded warrants. The warrants were acquired on April 14, 2026, as part of a PIPE financing agreement for an aggregate consideration of approximately $2.5 million. This follows previous transactions including the company's 2025 merger with Inmagene Biopharmaceuticals and a subsequent 1-for-12 reverse stock split. Otello Stampacchia currently serves on the Issuer's board of directors. The reporting persons acquired the securities for investment purposes and may engage in discussions with management regarding the company's business strategy, capitalization, or potential corporate transactions. Additionally, the reporting persons have secured registration rights for the resale of the warrant shares.